- Home
- HHS vs GBIO Comparison
HHS vs GBIO Comparison
Compare HHS & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- GBIO
- Stock Information
- Founded
- HHS 1923
- GBIO 2016
- Country
- HHS United States
- GBIO United States
- Employees
- HHS N/A
- GBIO N/A
- Industry
- HHS Advertising
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- GBIO Health Care
- Exchange
- HHS Nasdaq
- GBIO Nasdaq
- Market Cap
- HHS 30.3M
- GBIO 29.2M
- IPO Year
- HHS N/A
- GBIO 2020
- Fundamental
- Price
- HHS $4.03
- GBIO $0.39
- Analyst Decision
- HHS
- GBIO Strong Buy
- Analyst Count
- HHS 0
- GBIO 4
- Target Price
- HHS N/A
- GBIO $7.33
- AVG Volume (30 Days)
- HHS 31.2K
- GBIO 1.1M
- Earning Date
- HHS 08-07-2025
- GBIO 08-06-2025
- Dividend Yield
- HHS N/A
- GBIO N/A
- EPS Growth
- HHS N/A
- GBIO N/A
- EPS
- HHS N/A
- GBIO N/A
- Revenue
- HHS $181,355,000.00
- GBIO $24,556,000.00
- Revenue This Year
- HHS $6.54
- GBIO N/A
- Revenue Next Year
- HHS N/A
- GBIO N/A
- P/E Ratio
- HHS N/A
- GBIO N/A
- Revenue Growth
- HHS N/A
- GBIO 146.47
- 52 Week Low
- HHS $3.24
- GBIO $0.30
- 52 Week High
- HHS $8.80
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- HHS 40.53
- GBIO 52.02
- Support Level
- HHS $3.61
- GBIO $0.32
- Resistance Level
- HHS $4.05
- GBIO $0.36
- Average True Range (ATR)
- HHS 0.57
- GBIO 0.03
- MACD
- HHS 0.01
- GBIO 0.00
- Stochastic Oscillator
- HHS 24.19
- GBIO 81.00
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.